Login to Your Account



PTO Appeal Reverses on Idenix; Gilead Holds Cards in HIV Case

By Randy Osborne
Staff Writer

Tuesday, March 26, 2013
Having taken one step forward, Idenix Pharmaceuticals Inc. got pushed one back when the U.S. Patent and Trademark Office (USPTO) appeals board flipped a decision made earlier that favored Idenix over Gilead Pharmaceuticals Inc. in an interference dispute over patents related to hepatitis C virus (HCV) drugs.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription